ChemoCentryx, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2016-12-22: Form 8-K; Period of report 2016-12-22; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2016-11-07: Form 8-K; Period of report 2016-11-07; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2016-10-25: Form 8-K; Period of report 2016-10-20; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2016-10-20: Form 8-K; Period of report 2016-10-17; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure; Details 5.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2016-12-22 | 8-K | 2016-12-22 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d275906d8k.htm |
| 2016-11-07 | 8-K | 2016-11-07 | 2.02 Results of Operations and Financial Condition | 2.02 On November 7, 2016, ChemoCentryx, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2016. | d273699d8k.htm |
| 2016-10-25 | 8-K | 2016-10-20 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Effective as of October 20, 2016, Susan M. Kanaya, the current Senior Vice President, Financial, Chief Financial Officer and Secretary of ChemoCentryx, Inc. (the “Company”), was promoted to the position of Executive Vice President, Chief Financial and Administrative Officer and Secretary of the Company. | d270768d8k.htm |
| 2016-10-20 | 8-K | 2016-10-17 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 5.02 Effective as of October 17, 2016, upon the recommendation of the Nominating and Corporate Governance Committee, and pursuant to the bylaws of ChemoCentryx, Inc. (the “Company”), the Board of Directors (the “Board”) of the Company appointed Henry K. McKinnell, Jr., Ph.D., age 73, to fill a vacancy on the Board. 7.01 On October 20, 2016, the Company issued a press release announcing Dr. McKinnell’s appointment. | d255641d8k.htm |
| 2016-08-08 | 8-K | 2016-08-08 | 2.02 Results of Operations and Financial Condition | 2.02 On August 8, 2016, ChemoCentryx, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2016. | d232406d8k.htm |
| 2016-05-27 | 8-K | 2016-05-26 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 ChemoCentryx, Inc. (the “Company”) held its annual meeting of stockholders on May 26, 2016. | d194579d8k.htm |
| 2016-05-12 | 8-K | 2016-05-09 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 3.02 Reference is made to the disclosure under Item 1.01 of this Current Report on Form 8-K, which is incorporated in this Item 3.02 by reference. | d183827d8k.htm |
| 2016-05-10 | 8-K | 2016-05-10 | 2.02 Results of Operations and Financial Condition | 2.02 On May 10, 2016, ChemoCentryx, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2016. | d191074d8k.htm |
| 2016-03-14 | 8-K | 2016-03-14 | 2.02 Results of Operations and Financial Condition | 2.02 On March 14, 2016, ChemoCentryx, Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2015. | d154919d8k.htm |
| 2016-03-09 | 8-K | 2016-03-07 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 7, 2016, the Compensation Committee (the “Committee”) of the Board of Directors of ChemoCentryx, Inc. (the “Company”) approved cash bonuses to be paid to the executive officers listed below (the “NEOs”) for the 2015 fiscal year and approved and awarded the stock options and restricted stock units listed below to the NEOs under the Company’s 2012 Equity Incentive Award Plan. | d157775d8k.htm |